



Williamson County

January Benefit Committee Meeting

January 18, 2023




Agenda


- Financials
 - Trend Update- Monthly Paid Claims
 - Large Claims over \$50,000
- United Healthcare Updates
- Strategic Considerations

Financials

Medical Trend Rolling 12




Medical Trend PCL




Pharmacy Trend Rolling 12

Look-Back Rolling 12 Rx Claims



Pharmacy Trend PCL



High-Cost Claimants

Claimant ID	Relationship Description	Claimant Coverage Status	Medical Diagnosis Code Description	RX Standard Therapeutic Class Description	*Derived Claim Status	Medical Paid	Rx Paid	Total Paid
Claimant 1	SPOUSE	ACTIVE	PARKINSONS DISEASE	ANTIPARKINSON	OPEN	\$460,755.02	\$107,082.24	\$567,837.26
Claimant 2	EMPLOYEE	ACTIVE	MALIG NEO RT KIDNEY NO RENAL PELVIS	ANTINEOPLASTICS	OPEN	\$183,901.60	\$209,495.77	\$393,397.37
Claimant 3	SPOUSE	ACTIVE	MYELODYSPLASTIC SYNDROME UNS	ANTINEOPLASTICS	OPEN	\$99,317.81	\$216,834.62	\$316,152.43
Claimant 4	CHILD	ACTIVE	SINGLE LIVEBORN INFANT DELIV C-SECT	GLUCOCORTICOIDS	OPEN	\$299,557.83	\$405.58	\$299,963.41
Claimant 5	EMPLOYEE	ACTIVE	MALIG NEO UNS PART LT BRONCH/LUNG	ANTINEOPLASTICS	OPEN	\$181,931.53	\$116,500.76	\$298,432.29
Claimant 6	SPOUSE	ACTIVE	MALIG NEO UNS PART RT BRONCHU/LUNG	ANTINEOPLASTICS	OPEN	\$143,108.98	\$132,878.07	\$275,987.05
Claimant 7	EMPLOYEE	TERMED	MALIG NEO UNS PART UNS BRONCH/LUNG	ANTINEOPLASTICS	CLOSED	\$163,180.22	\$50,708.04	\$213,888.26
Claimant 8	EMPLOYEE	ACTIVE	SPINAL STENOSIS LUMBAR REGION NO NC	OPHTHALMIC PREPARATIONS	OPEN	\$199,751.06	\$4,882.04	\$204,633.10
Claimant 9	EMPLOYEE	TERMED	DSPL IT FX RT FEMUR INITIAL CLOS FX	ALL OTHER DERMATOLOGICALS	CLOSED	\$105,292.94	\$78,039.73	\$183,332.67
Claimant 10	EMPLOYEE	TERMED	POLYP OF COLON	ANTINEOPLASTICS	CLOSED	\$30,643.88	\$145,459.30	\$176,103.18
Claimant 11	EMPLOYEE	ACTIVE	ACUTE SUBACUTE INFECTV ENDOCARDITIS	NO STANDARD THERAPEUTIC CLASS CODE	OPEN	\$167,446.00	\$1,591.43	\$169,037.43
Claimant 12	EMPLOYEE	ACTIVE	END STAGE RENAL DISEASE	ANTIARTHRITICS	OPEN	\$93,096.31	\$52,767.53	\$145,863.84
Claimant 13	EMPLOYEE	TERMED	CMPL TRAUM AMP KNEE LVL RT LEG INIT		CLOSED	\$144,050.89		\$144,050.89
Claimant 14	EMPLOYEE	ACTIVE	OTHER SPECIFIED SEPSIS	MISCELLANEOUS	OPEN	\$130,984.84	\$4,349.11	\$135,333.95
Claimant 15	EMPLOYEE	TERMED	PRESSURE ULCER LEFT BUTTOCK STAGE 4	DIABETIC THERAPY	CLOSED	\$133,037.20	\$1,466.43	\$134,503.63
Claimant 16	EMPLOYEE	ACTIVE	ESSENTIAL PRIMARY HYPERTENSION	MISCELLANEOUS	OPEN	\$2,237.19	\$127,461.97	\$129,699.16
Claimant 17	EMPLOYEE	ACTIVE	GASTR ULCR UNS AC/CHRN W/O HEM/PERF	MISCELLANEOUS	OPEN	\$2,911.86	\$122,915.22	\$125,827.08
Claimant 18	EMPLOYEE	ACTIVE	HALLUX VALGUS ACQUIRED LEFT FOOT	ANTICOAGULANTS	OPEN	\$115,358.82	\$832.69	\$116,191.51
Claimant 19	SPOUSE	ACTIVE	RHEUMATOID ARTHRITIS UNSPECIFIED	OTHER THERAPEUTIC CLASS	OPEN	\$114,221.90	\$1,791.60	\$116,013.50
Claimant 20	SPOUSE	ACTIVE	CALCULUS KIDNEY W/ CALCULUS URETER	ANTIARTHRITICS	OPEN	\$18,934.51	\$72,896.51	\$91,831.02
Claimant 21	SPOUSE	ACTIVE	LUNG TRANSPLANT STATUS	BRONCHIAL DILATORS	OPEN	\$81,532.32	\$10,097.25	\$91,629.57
Claimant 22	EMPLOYEE	ACTIVE	PSORIASIS VULGARIS	ALL OTHER DERMATOLOGICALS	OPEN	\$626.17	\$82,995.21	\$83,621.38
Claimant 23	SPOUSE	ACTIVE	ANEURYSM OF CAROTID ARTERY	ANTISPASMODIC AND ANTICHOLINERGIC AGENT	CLOSED	\$81,933.33	\$679.81	\$82,613.14
Claimant 24	EMPLOYEE	ACTIVE	COVID-19	DIABETIC THERAPY	OPEN	\$64,903.75	\$15,812.01	\$80,715.76
Claimant 25	EMPLOYEE	ACTIVE	ENC SCREEN MALIG NEOPLASM COLON	ALL OTHER DERMATOLOGICALS	OPEN	\$4,534.72	\$75,830.81	\$80,365.53
Claimant 26	SPOUSE	ACTIVE	BILATERAL PRIM OSTEOARTHRITIS KNEE	OTHER THERAPEUTIC CLASS	OPEN	\$79,873.52	\$106.77	\$79,980.29
Claimant 27	EMPLOYEE	ACTIVE	ASHD NATIVE CA W/UNSTABLE AP	DIABETIC THERAPY	OPEN	\$67,899.52	\$11,289.22	\$79,188.74
Claimant 28	SPOUSE	ACTIVE	UNSPECIFIED CONVULSIONS	ANTIEMETICS	OPEN	\$78,061.21	\$846.82	\$78,908.03
Claimant 29	EMPLOYEE	ACTIVE	UNI PRIM OSTEOARTHRITIS RT KNEE	DIABETIC THERAPY	OPEN	\$61,438.63	\$17,144.87	\$78,583.50
Claimant 30	EMPLOYEE	ACTIVE	ASHD NATIVE CA W/UNSTABLE AP	ANTICOAGULANTS	CLOSED	\$73,617.39	\$2,284.18	\$75,901.57



United Healthcare Updates


celebrate.
embrace.
innovate.
protect.
Hope
innovate.
protect.
embrace.
Nurture.
Believe.
Commit.

Strategic Considerations

The Science of Bexa



- No equivalently accurate technology
- Proprietary mechanical and software components
- Continuous AI-driven software evolution further increases accuracy and simplifies training
- Wireless handheld sensor with secure Bluetooth connectivity to high-powered tablet computer
- Unique, high resolution, capacitive sensor array flexibly conforms to breast shape



- Highest sensitivity for mass detection of any modality: 89.3 to 92% sensitive for masses as small as 5mm
- Lowest rate of false positive studies
- Simple study results do not require physician interpretation
- 20-minute average exam time
- 10 days, 40 women examined, training process
- Highly portable

Brest exams with Bexa drive adoption



Bexa is a small handheld sensor that connects to a tablet and operates in an intelligent cloud ecosystem



FDA 510K cleared
class 2 medical device



AMA CPT code 0422T

A breast exam with Bexa is much like an ultrasound (but much more accurate). As part of a breast exam, the Bexa sensor is moved across the lubricated surface of the breast with light pressure, and results are displayed on a tablet that both woman and examiner can see and understand




Highly Adopted

- convenient - <30 minutes total time from dressed to exam to dressed
- painless
- no radiation
- immediate results
- effective in younger women

>95%

of women experiencing a breast exam with Bexa will have the exam again, and refer co-workers, friends and family

The reasons for this are simple and consistent



On Site

**Bexa Examiner: Female
ARDMS registered US tech**

1

breast exam with Bexa breast
tissue mapping

89.3 - 92% sensitivity for masses \geq 5mm

masses discovered
in 8% of women

2

US of all discovered
masses, remotely
interpreted

**only 3% of
women
require referral**

Bexa is for:

- Women 40+ who elect to avoid annual mammography – for 20 years this has represented 62% to 78% of U.S. women 40+
- African American women who should start early detection at age 35 due to earlier onset of breast cancer (on average 3-4 years earlier than a non-African American population)
- Women who want to begin early detection at younger ages – Bexa has no side effects and is effective in younger women




Low-cost

- **1/3 to 1/2 the cost of traditional exam process**
- Minimal number of follow-up imaging studies: 3% versus 12%
- **78% less expensive** than traditional early detection



Voluntary Benefits Focus



Voluntary Benefits offer members the opportunity for additional reimbursements when Deductibles and OOP limits are increasing.



Thank
you.